Evaluation of serum IgM and IgG antibodies in COVID?19 patients by enzyme linked immunosorbent assay

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sweeping the world since end of 2019. The titer change antibodies against SARS-CoV-2 needs to be further clarified, clinical and preventive value still investigated. An enzyme-linked immunosorbent assay (ELISA) was established by coating with recombinant spike protein used detect serum immunoglobulin M (IgM) G (IgG) in disease 2019 patients evaluate pattern changes antibodies. specificity ELISA for detection IgM IgG were 96% (144/150) 100% (150/150), respectively. sensitivity (150/150) IgM, 99.3% (149/150) IgG. SARS-CoV-2-SP-IgM SP-IgG could detected on Day 1 hospitalization 12.5% patients, SP-IgM began decrease after reaching its peak at around 22–28 days, become negative Month 3 30% 7 79% these onset; reached kept a high level within longest observation period 4 months, it dropped very sharply months. positive rates higher than those reverse transcription-polymerase chain reaction 4. indirect has good sensitivity. appeared almost simultaneously early stage, not maintain plateau Our data will help develop diagnosis vaccine SARS-CoV-2.